IFN). The nasal symptoms were evaluated monthly for 3 months, with test score symptoms questionary 4 (TSSQ4) and auto-evaluation by scale Linker. Results: We studied 94 AR patients (50% women and 50% men, range age between 5 and 40 years). Indoor antigens (mites, house dust and cockroach) were the main cause of allergy. Allergic patients had more eosinophiles and IgE than the healthy controls (P , 0.05). The number of CD81 lymphocytes was slightly reduced in group 2 after treatment (P , 0.05), whereas the amount of IL-4 and IFN ƒnwere increased in both groups (P , 0.005) and the amount of IL-10 was significantly increased in group 1 (P , 0.01) after treatment. Clinical evaluation was with initial TSSQ4 of 11.6 before handling and 5.1 (44%) after, with significant improvement (P , 0.0001) and Likert score was reduced 69% than the star the treatment. Conclusions: The TF along with SLITAE in the treatment of patients with RA did not alter the clinical improvement induced by SLITAE alone for 3 months of treatment, but the combination increased production of IL 10 and production of IFNg. Background: Allergy immunotherapy tablets (AIT) provides a safer and more convenient alternative to subcutaneous specific immunotherapy treatment. However, severe adverse events occur infrequently. These events are rare and therefore pooled safety data from 1 phase II/III and 6 phase III clinical trials (5 in adults, 2 in children (5-17 years)) with grass AIT (Grazax, Phleum pratense 75,000 SQ-T/2800 BAU, ALK, Denmark) were analysed. Method: All trials were randomised, double-blind, placebo-controlled multi-centre trials. Subjects suffered from grass pollen induced allergic rhinoconjunctivitis with or without asthma, had positive skin prick test and specific IgE to Phleum pratense. Subjects received once-daily sublingual treatment with grass AIT or placebo for approximately 24 weeks. The 5 adult trials comprised 2095 treated subjects (AIT ¼ 1060, placebo ¼ 1035) and the 2 children trials comprised 597 treated subjects (AIT ¼ 301, placebo ¼ 296). Adverse events were assessed by the investigator as treatment-related (possible or probable) or unlikely related and for seriousness. Application site-related events were defined as adverse events in relation to the oral cavity. Results: In the adult trials, 71% of AIT-treated subjects reported treatmentrelated adverse events compared to 24% for placebo. In the children trials the corresponding numbers were 63% for AIT and 27% for placebo. Of the AITtreated subjects 2 children (0.7%) and 32 adults (3.0%) experienced severe treatment-related events. The odds for severe events was 4.7 times lower in children compared to adults (odds-ratio with 95% CI, 0.22 [0.025-0.85], P ¼ 0.019). Both AIT-treated children (0.7%) and 18 (1.7%) of the AIT-treated adults experienced severe treatment-related events that were application siterelated. The odds for having severe related application site adverse events was 2.6 times lower in children compared to adults (odds-ratio with 95% CI, 0.39 [0.04-1.63], P ¼ 0.27, not statistically significant). No serious treatment-related adverse events were reported. Conclusion: This pooled analysis of over 2000 subjects in 7 clinical trials shows that the risk of experiencing severe treatment-related adverse events was significantly lower in children compared to adults when treated with of Timothy grass allergy immunotherapy tablets. This analysis provides evidence that Timothy grass AIT is an important and safe immunotherapy treatment option in children with grass pollen induced rhinoconjunctivitis. 6 Stallergenes, Antony Cedex, France. Background: A 5-year study of adults with grass-pollen related rhinoconjunctivitis has demonstrated the sustained efficacy of discontinuous treatment with a 300 IR sublingual tablet of 5-grass pollen allergen extract, initiated 4 or 2 months before each pollen season and continued for its duration for 3 consecutive years. Here we report on the persistence of efficacy during the first of 2 post-treatment pollen seasons. Methods: 633 adults were randomized to either placebo or one of 2 active groups receiving pre-and co-seasonal treatment for 3 pollen seasons starting each year either 4 months [4M] or 2 months [2M] prior to the pollen season. Patients were followed during the subsequent, treatment-free, grass pollen season. The primary endpoint for the Year 4 assessment of the post-treatment long-term efficacy was the Average Adjusted Symptom Score (AAdSS, adjusting the Rhinoconjunctivitis Total Symptom Score for rescue medication usage) during the fourth pollen period. Secondary efficacy criteria included the Average Rescue Medication Score (ARMS) and the overall Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) score. Results: Statistically significant differences compared to Placebo in the mean AAdSS during the Year 4 pollen period were observed for both 300 IR (4M) and 300 IR (2M). The treatment effect for 300 IR (4M) was estimated as the difference in LS Means of 21.14 (95% CI, [22.03 to 20.26], P ¼ 0.0114), corresponding to a relative LS Mean difference from Placebo of 222.9%, whilst the treatment effect for 300 IR (2M) is estimated as the difference in LS Means of 21.43 (95% CI, [22.32 to 20.53]), P ¼ 0.0019), corresponding to a relative LS Mean difference from Placebo of 228.5%. The primary results were confirmed over the worst pollen period. Compared to placebo, the active treatment groups (4M and 2M) also showed a statistically significant LS Mean difference in ARMS (224.6%; P ¼ 0.00184 and 227.9%; P ¼ 0.0082) and in overall RQLQ score (232.8%; P ¼ 0.0001 and 237.6%; P , 0.0001). No unexpected risk was identified in this study. Conclusions: The post-treatment, long-term efficacy of 300 IR sublingual tablets of grass pollen allergen extract was demonstrated during the first of 2 post-treatment pollen seasons. This persistent improvement was clinically meaningful to patients.
Background: Allergy immunotherapy tablets (AIT) provides a safer and more convenient alternative to subcutaneous specific immunotherapy treatment. However, severe adverse events occur infrequently. These events are rare and therefore pooled safety data from 1 phase II/III and 6 phase III clinical trials (5 in adults, 2 in children (5-17 years)) with grass AIT (Grazax, Phleum pratense 75,000 SQ-T/2800 BAU, ALK, Denmark) were analysed. Method: All trials were randomised, double-blind, placebo-controlled multi-centre trials. Subjects suffered from grass pollen induced allergic rhinoconjunctivitis with or without asthma, had positive skin prick test and specific IgE to Phleum pratense. Subjects received once-daily sublingual treatment with grass AIT or placebo for approximately 24 weeks. The 5 adult trials comprised 2095 treated subjects (AIT ¼ 1060, placebo ¼ 1035) and the 2 children trials comprised 597 treated subjects (AIT ¼ 301, placebo ¼ 296). Adverse events were assessed by the investigator as treatment-related (possible or probable) or unlikely related and for seriousness. Application site-related events were defined as adverse events in relation to the oral cavity. Results: In the adult trials, 71% of AIT-treated subjects reported treatmentrelated adverse events compared to 24% for placebo. In the children trials the corresponding numbers were 63% for AIT and 27% for placebo. Of the AITtreated subjects 2 children (0.7%) and 32 adults (3.0%) experienced severe treatment-related events. The odds for severe events was 4.7 times lower in children compared to adults (odds-ratio with 95% CI, 0.22 [0.025-0.85], P ¼ 0.019). Both AIT-treated children (0.7%) and 18 (1.7%) of the AIT-treated adults experienced severe treatment-related events that were application siterelated. The odds for having severe related application site adverse events was 2.6 times lower in children compared to adults (odds-ratio with 95% CI, 0.39 [0.04-1.63], P ¼ 0.27, not statistically significant). No serious treatment-related adverse events were reported. Conclusion: This pooled analysis of over 2000 subjects in 7 clinical trials shows that the risk of experiencing severe treatment-related adverse events was significantly lower in children compared to adults when treated with of Timothy grass allergy immunotherapy tablets. This analysis provides evidence that Timothy grass AIT is an important and safe immunotherapy treatment option in children with grass pollen induced rhinoconjunctivitis. 6 Stallergenes, Antony Cedex, France. Background: A 5-year study of adults with grass-pollen related rhinoconjunctivitis has demonstrated the sustained efficacy of discontinuous treatment with a 300 IR sublingual tablet of 5-grass pollen allergen extract, initiated 4 or 2 months before each pollen season and continued for its duration for 3 consecutive years. Here we report on the persistence of efficacy during the first of 2 post-treatment pollen seasons. Methods: 633 adults were randomized to either placebo or one of 2 active groups receiving pre-and co-seasonal treatment for 3 pollen seasons starting each year either 4 months [4M] or 2 months [2M] prior to the pollen season. Patients were followed during the subsequent, treatment-free, grass pollen season. The primary endpoint for the Year 4 assessment of the post-treatment long-term efficacy was the Average Adjusted Symptom Score (AAdSS, adjusting the Rhinoconjunctivitis Total Symptom Score for rescue medication usage) during the fourth pollen period. Secondary efficacy criteria included the Average Rescue Medication Score (ARMS) and the overall Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) score. Results: Statistically significant differences compared to Placebo in the mean AAdSS during the Year 4 pollen period were observed for both 300 IR (4M) and 300 IR (2M). The treatment effect for 300 IR (4M) was estimated as the difference in LS Means of 21.14 (95% CI, [22.03 to 20.26], P ¼ 0.0114), corresponding to a relative LS Mean difference from Placebo of 222.9%, whilst the treatment effect for 300 IR (2M) is estimated as the difference in LS Means of 21.43 (95% CI, [22.32 to 20.53] ), P ¼ 0.0019), corresponding to a relative LS Mean difference from Placebo of 228.5%. The primary results were confirmed over the worst pollen period. Compared to placebo, the active treatment groups (4M and 2M) also showed a statistically significant LS Mean difference in ARMS (224.6%; P ¼ 0.00184 and 227.9%; P ¼ 0.0082) and in overall RQLQ score (232.8%; P ¼ 0.0001 and 237.6%; P , 0.0001). No unexpected risk was identified in this study. Conclusions: The post-treatment, long-term efficacy of 300 IR sublingual tablets of grass pollen allergen extract was demonstrated during the first of 2 post-treatment pollen seasons. This persistent improvement was clinically meaningful to patients. College of Medicine, National Cheng Kung University, Tainan, Taiwan. Background: Escherichia coli heat-labile enterotoxin (LT) with different mutant forms has been used as adjuvant for vaccines due to its ability to enhance immune response to specific antigen in vivo. We hypothesis that LTS61K or LTS61K mixed with dust mite allergen, Der p, (LTS61K/Der p) can modulate dendritic cells (DCs) s' functions thus alleviate allergen-induced airway inflammation.
WAO Journal February 2012
Abstracts Ó 2012 World Allergy Organization
S19
Copyright @ World Allergy Organization. Unauthorized reproduction of this article is prohibited. 2012
